Complex Small Molecules Are Changing Drug R&D

Modern small molecule drug discovery is becoming more structurally complex with targeted protein degraders, covalent agents, and advanced kinase inhibitors requiring integrated discovery, development, and manufacturing capabilities. WuXi AppTec highlights how unified CRDMO platforms that connect all stages under one quality system can compress timelines and improve translational success rates by enabling parallel workflows and early process development decisions.